Clinical Trial Update: A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]

View source ↗

Summary

This update reports the results of a Phase 2 study of duvelisib in participants with relapsed or refractory peripheral T-cell lymphoma. The trial was sponsored …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: SecuraBio | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-02-28